Media Coverage


CRI Annual Summer Party a Success. Bay Windows. July 23, 2015.
Provincetown’s Red Inn Hosts Fabulous, Feel-Good Summer Party Fundraiser for CRI. Boston Spirit Magazine. July 17, 2015.
Diminishing research dollars sparks disease comparisons, competition, while HIV advocates say now is not the time to ease efforts. Science Speaks: HIV & TB News. June 15, 2015.
Bristol-Myers Squibb Submission for New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1. Reuters UK. April 14, 2014.
Miller S.R. Healthy Investment: The Campbell Foundation Funds HIV/AIDS Research Projects Around The Globe. The Boca Raton Observer, p. 162. February 2014.
Gilead Snags EC, FDA Approval on HIV Drug. Drug Discovery & Development. December 16, 2013.
Highleyman L. Eviplera works well regardless of viral load or CD4 count, may improve lipid levels. NAM. October 11, 2013.
LeFae B. Trials without tribulations: What you should know about the design, participation, and goals of clinical trials. Positively Aware. September/October 2013.
10th Annual CRI Summer Party breaks records. Bay Windows. July 25, 2013.
Baulf D. Omar Sharif Jr. :: Talking with the Out ’Actor-vist.’ EDGE. July 19, 2013.
Fieldhouse R. Stribild Speaking. BASELINE HIV. July 10, 2013.
Fowler G. HIV Treatment Highlights from IAS 2013 [VIDEO]. July 7, 2013.
Beckham B. AIDS ride uses every penny for a purpose. Boston Globe. September 9, 2012.
John and Marc—riding H2B for love and to make a difference Bay Windows. August 8, 2012.
Community Research Initiative Red Hot Jazz at the Red Inn in Provincetown. Bay Windows. July 26–August 1, 2012.
Let the bidding begin! Provincetown Banner. July 20, 2012.
Liuzza M. Kagan to do charity bike ride. Belmont Citizen-Herald. July 19, 2012.
Phelps R. Provincetown art show & auction to benefit Community Research Initiative in Boston. Provincetown Banner. July 12, 2012.
Famulare T. Spending the Summer In Ptown? Boston Spirit. July/August 2012.
Think Locally: Red Hot Jazz at the Red Inn. Bay Windows. June 28–July 3, 2012.
CRI Boston Beach Party: Esther Esther 3D. Boston Spirit. May/June 2012.
Community Research Initiative (CRI) Boston Beach Party: EstherEsther 3D Bay Windows. March 29–April 4, 2012.
HIV Treatment Update From CROI 2012. The Body Pro. March 13, 2012.
Fowler G. CROI: HIV Drug Development News from CROI 2012. March 9, 2012.
Borg E. Esther!Esther! Boston Spirit. March/April 2012.
Levin J. Conference reports for Natap: CROI 2012. March 8, 2012.
Smith M. ICAAC: One-Pill HIV regimen tied to less inpatient care. MedPage Today. September 23, 2011.
CRI Circle of Friends Summer Party 2011. Boston Spirit. Sept/Oct 2011.
Cohen C, Frank I, Hardy W D, Sax P. Assessing best practices in HIV/AIDS therapy. August, 2011.
CRI fundraiser rocks! Provincetown Banner. July 21, 2011.
Rilpivirine as effective, better tolerated than efavirenz. European AIDS Treatment Group. July 21, 2011.
Drug development news from IAS 2011 [Video with Cal Cohen]. HIV and July 20, 2011.
Hitt E, PhD. Rilpivirine noninferior to efavirenz in HIV patients. Medscape News Today. July 18, 2011. registration required
Levin J. Conference reports for Natap. July 17, 2011.
Rilpivirine bested efavirenz combo in HIV. Infectious Disease News. July 15, 2011.
Rilpivirine has non-inferior efficacy to efavirenz for HIV-1. DoctorsLounge. July 15, 2011.
Latest antiretroviral drug against HIV-1 infection, rilpivirine, an effective alternative to first choice efavirenz, with fewer side effects. The Lancet Press Office. July 15, 2011.
Smith M. Untreated HIV patients have new drug option. MedPage Today. July 14, 2011. registration required
Cohen C. The Research and Clinical Care Partnership. HIV Specialist. Spring 2011.
Myles H. Edurant (Rilpivirine): The HIV treatment dating game just got more interesting: an interview with Cal Cohen, M.D. The Body Pro. May 26, 2011.
CRI’s Summer Party. Boston Spirit. Sept-Oct, 2010.
Smith M. IAC: New HIV drug matches old standard. MedPage Today. July 23, 2010.
Alcorn K. Rilpivirine (TMC278) matches efavirenz in phase 3 studies, with fewer side effects. July 22, 2010.
Evans D. Rilpivirine has similar efficacy and better tolerability than Sustiva. July 22, 2010.
TMC278 pivotal phase 3 clinical trials achieve primary objective. PR Newswire. July 22, 2010.
Shaughnessey D. Dad’s death spurs commitment to AIDS cause. Lowell Sun. June 1, 2010.
Sackowitz K. Dracut couple will host AIDS benefit. Boston Globe. June 1, 2010.
Mehta S, Cohen C. The fourteenth annual HIV drug guide. Positively Aware. March-April 2010.
Randall T. Gilead Quad AIDS pill safer, better than Atripla. Bloomberg Business Week. February 18, 2010.
Smith M. CROI: new drug combo safe, potent. MedPage Today. February 18, 2010.
Highleyman L. New CCR5 antagonist TBR-652 shows good antiviral activity in early study. AIDS Map. February 18, 2010.
Horn T. New CCR5 antagonist shows promise in early study. AIDS Meds. February 18, 2010.
Susman E. CROI: new anti-HIV drug cuts viral load. MedPage Today. February 18, 2010.
Helfand M. The new quad on the block: four-drug fixed dose combination with a novel booster sails through phase 2 trials. The Body. February 18, 2010.
Grogan K. Excitement grows over Gilead’s HIV combo Quad. PharmaTimes. February 18, 2010.
Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla. The Medical News. February 18, 2010.
Mascolini M. QUAD four-in-one pill as strong as Atripla, but a kidney concern arises. February 17, 2010.
Horn T. Quad pill and boosting drug show well in studies. February 17, 2010.
Goldman B. Breaking research from IAS 2009: A discussion with HIV/AIDS activists Bob Munk and Matt Sharp. The Body. August 26, 2009.
Highleyman L. FOTO study finds 5 days on, 2 days off treatment strategy maintains HIV suppression while reducing cost. HIV and August 7, 2009.
Goldman B. HIV treatment highlights from IAS 2009: An interview with Joel Gallant, M.D., M.P.H. The Body Pro. August 5, 2009.
Evans D. Efavirenz five-days-on, two-off, works as well as continuous treatment. July 22, 2009.
FOTO Study: 5-Days-On, 2-Days-Off dosing strategy appears comparable to continuous HAART in patients with virologic suppression on efavirenz, tenofovir, and emtricitabine. Clinical Care Options HIV [online]. July 21, 2009. registration required
Susman E. IAS: Patients maintain HIV suppression with 2-day drug breaks. July 20, 2009.
Levin J. The FOTOSTUDY: 48 week results to assess durability of the strategy of taking efavirenz, tenofovir and emtricitabine five-days-on, two-days-off each week in virologically suppressed patients. July 19-22, 2009.
Mascolini M. Raltegravir rescue regimens do well with or without a PI. July 2009.
Hunter M and LaMarche U. Full plate: Diffa’s Dining by Design event brought a lot to the table: inspired settings, fine dining, and a noble cause. Boston Common. January 2009.
Kaufman H. Turning the tables for a good cause.The Boston Globe. December 11, 2008.
Eating in style.The Boston Globe. December 4, 2008.
Harbor to the Bay gives money away. Bay Windows. December 4, 2008.
Riccardi V. Creative Cuisine: At Dining by Design, charity has never tasted so sweet. Boston Common. December 2008.
Treatment interruptions may still have a future. November 13, 2008.
Mascolini M. Risks and benefits of 5 days on/2 days off in the FOTO study November 17, 2008.
Atripla shown effective in five-days-a-week regimen. AIDSinfo At-a-Glance [online]. November 14, 2008 (48).
Cairns G. Treatment breaks set for a come-back? November 12, 2008.
Lauerman J. Gilead AIDS pill effective in study with weekends off. November 11, 2008.
Lauerman J. Glaxo’s Epzicom loses preferred status as HIV drug. Bloomberg. November 3, 2008.
U.S. Food and Drug Administration (FDA) approves PREZISTA OnceDaily as part of combination therapy for treatment-naïve adults with HIV-1 [press release]. Tibotec Pharmaceuticals. October 22, 2008.
Gorzka P, Wills T, Cohen C, DeJesus E, Elion R, Frank I, Moyle G, Sax P. Assessing best practices in HIV/AIDS therapy. IAC 2008 CME/CE Newsletter Update. August 2008.